Literature DB >> 11327116

Molecular genetics of prostate cancer.

J P Elo1, T Visakorpi.   

Abstract

The molecular mechanisms underlying the development and progression of prostate cancer are poorly understood. Epidemiological studies have suggested that 5-10% of all prostate cancers are familial, and numerous chromosomal loci have been associated with prostate cancer in multicentre linkage studies. However, no putative susceptibility genes harboured in these chromosomal regions have thus far been identified. Several recurrent chromosomal alterations in prostate cancer have been detected in comparative genomic hybridization (CGH) and loss of heterozygosity (LOH) analysis. The target genes for many of these aberrations are still not known. It seems that the androgen receptor (AR) signalling pathway plays a crucial role in both early development as well as in late progression of the disease. Both germ-line and somatic genetic alterations in the AR gene have been demonstrated in prostate cancer patients. The intention of this review is to summarize the current knowledge of molecular mechanisms in the development of prostate cancer.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11327116     DOI: 10.3109/07853890109002068

Source DB:  PubMed          Journal:  Ann Med        ISSN: 0785-3890            Impact factor:   4.709


  13 in total

1.  Anti-thrombin is expressed in the benign prostatic epithelium and in prostate cancer and is capable of forming complexes with prostate-specific antigen and human glandular kallikrein 2.

Authors:  Yue Cao; Ake Lundwall; Virgil Gadaleanu; Hans Lilja; Anders Bjartell
Journal:  Am J Pathol       Date:  2002-12       Impact factor: 4.307

Review 2.  Molecular biology in prostate cancer.

Authors:  José Ramón Cansino Alcaide; Luis Martínez-Piñeiro
Journal:  Clin Transl Oncol       Date:  2006-03       Impact factor: 3.405

3.  Amplification of EIF3S3 gene is associated with advanced stage in prostate cancer.

Authors:  O Saramäki; N Willi; O Bratt; T C Gasser; P Koivisto; N N Nupponen; L Bubendorf; T Visakorpi
Journal:  Am J Pathol       Date:  2001-12       Impact factor: 4.307

4.  Expression and gene copy number analysis of ERBB2 oncogene in prostate cancer.

Authors:  Kimmo J Savinainen; Outi R Saramäki; Marika J Linja; Ola Bratt; Teuvo L J Tammela; Jorma J Isola; Tapio Visakorpi
Journal:  Am J Pathol       Date:  2002-01       Impact factor: 4.307

5.  HER2 gene amplification in patients with prostate cancer: Evaluating a CISH-based method.

Authors:  Nazanin Sharifi; Arash Salmaninejad; Samira Ferdosi; Abolfazl Nesaei Bajestani; Malihe Khaleghiyan; Mehrdad Asghari Estiar; Mansour Jamali; Mohammad Reza Nowroozi; Abbas Shakoori
Journal:  Oncol Lett       Date:  2016-10-10       Impact factor: 2.967

Review 6.  Molecular pathology of prostate cancer.

Authors:  C Hughes; A Murphy; C Martin; O Sheils; J O'Leary
Journal:  J Clin Pathol       Date:  2005-07       Impact factor: 3.411

7.  The alteration of PTEN tumor suppressor expression and its association with the histopathological features of human primary hepatocellular carcinoma.

Authors:  X-W Wan; M Jiang; H-F Cao; Y-Q He; S-Q Liu; X-H Qiu; M-C Wu; H-Y Wang
Journal:  J Cancer Res Clin Oncol       Date:  2003-03-07       Impact factor: 4.553

8.  MYC and Prostate Cancer.

Authors:  Cheryl M Koh; Charles J Bieberich; Chi V Dang; William G Nelson; Srinivasan Yegnasubramanian; Angelo M De Marzo
Journal:  Genes Cancer       Date:  2010-06

9.  MYC overexpression induces prostatic intraepithelial neoplasia and loss of Nkx3.1 in mouse luminal epithelial cells.

Authors:  Tsuyoshi Iwata; Denise Schultz; Jessica Hicks; Gretchen K Hubbard; Laura N Mutton; Tamara L Lotan; Carlise Bethel; Matthew T Lotz; Srinivasan Yegnasubramanian; William G Nelson; Chi V Dang; MengMeng Xu; Uzoma Anele; Cheryl M Koh; Charles J Bieberich; Angelo M De Marzo
Journal:  PLoS One       Date:  2010-02-25       Impact factor: 3.240

Review 10.  Methods for the molecular analysis of cancer. An overview.

Authors:  Ken Mills
Journal:  Mol Biotechnol       Date:  2003-02       Impact factor: 2.695

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.